🦾Biomedical Engineering I Unit 10 Review

Regenerative medicine holds real promise for treating diseases that currently have no cure, but it also raises some of the most contested ethical questions in modern biomedical research. These range from debates about the moral status of embryos to concerns about equitable access to expensive new therapies. Understanding these ethical dimensions is just as important for biomedical engineers as understanding the science itself, because the choices made in research design and clinical translation directly affect patients and society.

Moral Status of Embryos

The central ethical tension in embryonic stem cell research comes down to one question: What is the moral status of a human embryo?

Some hold that life begins at conception, meaning an embryo deserves the same protections as a fully developed person. From this view, destroying an embryo to harvest stem cells is morally equivalent to taking a human life.
Others argue that early-stage embryos (typically blastocysts at around 5 days old) lack the features we associate with personhood, such as consciousness or the ability to feel pain, and that the potential to save lives through research justifies their use.

There's no scientific answer to this question. It's a philosophical and often religious one, which is exactly what makes it so difficult to resolve through policy alone.

Sources of Stem Cells

The source of stem cells matters enormously from an ethical standpoint.

Embryonic stem cells (ESCs) are derived from blastocysts, which requires destroying the embryo. The embryos used are typically surplus from in vitro fertilization (IVF) procedures and would otherwise be discarded. Supporters argue that using them for research is preferable to simply discarding them.
Adult stem cells can be harvested without harming the donor (e.g., from bone marrow or blood), but they are more limited in differentiation potential. They tend to be multipotent rather than pluripotent, meaning they can become several cell types but not all of them.
Induced pluripotent stem cells (iPSCs) are adult cells reprogrammed back to a pluripotent state. They avoid embryo destruction entirely, which sidesteps the main ethical objection. However, iPSCs can behave differently from true ESCs in some contexts, and reprogramming introduces its own technical challenges (e.g., potential for tumor formation).

Some ethicists argue that the existence of iPSCs makes embryonic stem cell research unnecessary. Others counter that ESCs remain the gold standard for pluripotency research and that restricting their use would slow down critical discoveries.

"Playing God" and Slippery Slope Concerns

Growing tissues or organs in a lab strikes some people as crossing a line into territory that should be left to nature or a higher power. Religious traditions vary on this, but common objections include:

Manipulating human biology at this level is "unnatural" and violates the sanctity of life.
Embryonic stem cell use could lead down a slippery slope toward the commodification of human life, designer babies, or human cloning.

The slippery slope argument is worth taking seriously, even if you disagree with it. History shows that technologies developed for one purpose can be repurposed in ways their creators didn't intend. That said, slippery slope reasoning alone doesn't prove that a particular practice is wrong; it highlights the need for strong regulatory frameworks.

Justice and Access

Regenerative medicine therapies are likely to be extremely expensive, at least initially. Consider that a single CAR-T cell therapy (a form of cell-based immunotherapy) can cost over $400,000 per patient.

If only wealthy individuals or well-funded health systems can afford these treatments, regenerative medicine could widen existing health disparities rather than reduce them.
Fair allocation of limited resources, such as donor cells, bioengineered organs, or specialized clinical expertise, is an ongoing ethical challenge.
Global disparities matter too. If cutting-edge regenerative therapies are available only in high-income countries, populations with the greatest disease burden may be left behind.

Embryonic Stem Cell Use: Arguments For vs. Against

This debate comes up repeatedly in bioethics, so it's worth seeing the core arguments side by side.

Arguments in Favor

ESCs are pluripotent, meaning they can differentiate into virtually any cell type in the body. This gives them the broadest therapeutic potential of any stem cell source.
The embryos used are typically surplus IVF embryos that would be discarded if not donated for research. Proponents argue this makes their use ethically preferable to waste.
The potential to develop treatments for conditions like spinal cord injury, Parkinson's disease, and type 1 diabetes represents an enormous benefit that, for many, outweighs concerns about embryo destruction.

Arguments Against

If you hold that life begins at conception, embryo destruction is morally unacceptable regardless of the potential benefits.
The availability of adult stem cells and iPSCs provides alternative paths that avoid embryo destruction. Opponents argue these alternatives should be prioritized.
Religious traditions, including many branches of Christianity and Islam, teach that embryos possess a sanctity that prohibits their instrumental use.
There is concern that normalizing embryo destruction for research could erode respect for human life more broadly, opening the door to practices like reproductive cloning or genetic selection of embryos for non-medical traits.

Risks and Benefits of Gene Editing

Gene editing, particularly using the CRISPR-Cas9 system, intersects with regenerative medicine because it can modify cells before they're used in therapies. CRISPR works by using a guide RNA to direct the Cas9 enzyme to a specific DNA sequence, where it makes a targeted cut that researchers can use to delete, repair, or insert genetic material.

Potential Benefits

CRISPR could correct disease-causing mutations at their source. Clinical trials are already underway for conditions like sickle cell anemia (caused by a single-point mutation in the hemoglobin gene) and beta-thalassemia.
Gene editing could make transplant organs more compatible by removing surface markers (such as certain HLA antigens) that trigger immune rejection, potentially increasing the supply of viable organs.
Beyond single-gene disorders, CRISPR research is exploring applications in cancer immunotherapy, antiviral treatments, and tissue engineering.

Risks and Ethical Concerns

Off-target effects occur when CRISPR cuts at unintended locations in the genome. These unintended edits could disrupt tumor suppressor genes or other critical sequences, potentially causing cancer or other serious health problems.
Enhancement vs. therapy is a blurry line. Using CRISPR to cure sickle cell disease is widely supported, but using it to select for traits like height or intelligence raises deep concerns about inequality and the commodification of human biology.
Germline editing (editing embryos so that changes are inherited by future generations) is the most controversial application. The 2018 case of He Jiankui, who edited the genomes of twin embryos in China, was widely condemned by the scientific community because:
- Long-term effects of germline changes are unknown.
- Future generations who inherit these edits never had the opportunity to consent.
- The risks were not justified by the potential benefits in that specific case.
Many countries, including the US (through funding restrictions) and most of Europe, prohibit or heavily restrict human germline editing. Some researchers argue it could eventually prevent devastating inherited diseases if safety can be demonstrated, but the consensus for now is that it's too risky.

Informed consent is a foundational principle of medical ethics: patients have the right to understand what a treatment involves, including its risks, benefits, and alternatives, before agreeing to it. Regenerative medicine makes this principle harder to apply in practice.

Challenges with Experimental Treatments

Because regenerative medicine is a relatively young field, many therapies are still in clinical trials. This creates specific consent challenges:

Unknown long-term risks. If a therapy has only been tested for a few years, you genuinely can't tell a patient what the 10- or 20-year outcomes look like. Consent forms must clearly communicate this uncertainty.
Complexity of the science. Patients need to understand concepts like stem cell differentiation, immune rejection, and genetic modification well enough to make a meaningful decision. This requires careful, accessible communication from the clinical team.
Right to refuse. Some patients may object to treatments involving embryonic stem cells or gene editing on moral or religious grounds. Patient autonomy means their refusal must be respected, even if clinicians believe the treatment would help.

Vulnerable Populations

Certain groups require extra ethical safeguards:

Children and individuals who lack decision-making capacity cannot provide their own informed consent. Surrogate decision-makers (usually parents or legal guardians) must weigh the risks and benefits on their behalf, guided by the patient's best interests.
Terminally ill patients or those with no remaining treatment options may feel desperate enough to accept experimental therapies they wouldn't otherwise consider. Consent in these situations must be scrutinized to ensure it's truly voluntary and not driven by a sense of having "nothing to lose."
Use of a patient's own cells (autologous therapies, such as growing skin grafts from a patient's skin cells) still requires consent. Patients should be told how their cells will be used, how long they'll be stored, and what happens to them after treatment.

🦾Biomedical Engineering I Unit 10 Review